Colchicine

Colchicine is one of the oldest medications still in clinical use, derived from the autumn crocus (*Colchicum autumnale*) and used for gout for over 2,000 years ^[1]. Its anti-inflammatory mechanism is distinct from NSAIDs, corticosteroids, and other anti-inflammatory agents.

Colchicine works primarily by binding to tubulin, a protein that forms the structural backbone (microtubules) of cells ^[2]. When colchicine binds tubulin, it prevents microtubule polymerization — the assembly of tubulin subunits into the cytoskeletal structures that cells need for shape, movement, and intracellular transport ^[1][2].

This has several important anti-inflammatory effects:

1. Inhibition of neutrophil migration: Neutrophils require microtubule-dependent movement to migrate to sites of urate crystal deposition. Colchicine reduces the influx of inflammatory white blood cells into gout-affected joints ^[2].

2. NLRP3 inflammasome inhibition: Colchicine blocks the assembly of the NLRP3 inflammasome, a critical inflammatory signaling complex activated by monosodium urate crystals. This prevents the production of interleukin-1-beta (IL-1B), the key cytokine driving gout inflammation ^[3].

3. Reduced superoxide production: Colchicine inhibits neutrophil superoxide generation and degranulation, further dampening the inflammatory response ^[2].

Importantly, colchicine does not lower uric acid levels — it is purely an anti-inflammatory that treats and prevents gout symptoms ^[1].

For an acute gout flare, the modern low-dose colchicine regimen (1.2 mg followed by 0.6 mg one hour later, total 1.8 mg) works best when started within 12-24 hours of symptom onset ^[4]. Most patients notice significant improvement within 24-48 hours.

The most common side effect is diarrhea, which occurs in up to 23% of patients even at low doses ^[1]. Nausea and vomiting may also occur. These GI effects were much more common with the old high-dose regimen (which is no longer recommended).

For flare prophylaxis during allopurinol initiation, low-dose colchicine (0.6 mg once or twice daily) is generally well tolerated with manageable GI side effects ^[4].

Critical safety point: tell your doctor about ALL medications you take, including antibiotics and antifungals. Certain common drugs (clarithromycin, erythromycin, ketoconazole, itraconazole, ritonavir, cyclosporine, diltiazem, verapamil) can cause dangerous colchicine accumulation ^[1].

Food: Colchicine can be taken with or without food ^[1]. Taking with food may reduce GI side effects. Food does not significantly affect the total absorption of colchicine.

Grapefruit: Avoid grapefruit and grapefruit juice during colchicine therapy ^[1]. Grapefruit inhibits CYP3A4 in the gut wall, increasing colchicine absorption and blood levels, which can increase toxicity risk given colchicine's narrow therapeutic window.

Alcohol: Alcohol should be avoided or limited during colchicine use. Alcohol can worsen gout by increasing uric acid production and impairing renal urate excretion. It may also worsen GI side effects (nausea, diarrhea) when combined with colchicine ^[4].

Purine-Rich Foods: While colchicine treats gout inflammation (not uric acid levels), patients should still moderate purine intake. Dietary triggers like beer, organ meats, and shellfish can provoke gout flares even during colchicine prophylaxis ^[4].

Acute Gout Flare: 1.2 mg at first sign of flare, then 0.6 mg one hour later (total 1.8 mg). No additional colchicine for at least 3 days ^[1][4]. Most effective when started within 12-24 hours of flare onset. This is the FDA-approved low-dose regimen that is as effective as the old high-dose regimen with far fewer GI side effects.

Gout Flare Prophylaxis: 0.6 mg once or twice daily during initiation of urate-lowering therapy (allopurinol, febuxostat). Continue for at least 3-6 months after achieving target urate ^[4].

Familial Mediterranean Fever: 1.2-2.4 mg/day in 1-2 divided doses. Titrate to response ^[1].

Pericarditis: 0.5 mg twice daily (or 0.5 mg daily if <70 kg) for 3 months (acute) or 6 months (recurrent) ^[5].

Renal Impairment: CrCl 30-80 mL/min: use with caution, consider dose reduction. CrCl <30 mL/min: reduce dose significantly. Hemodialysis: colchicine is not removed by dialysis ^[1].

Hepatic Impairment: Reduce dose. Severe hepatic impairment with renal impairment: colchicine is contraindicated ^[1].

Drug Interaction Dose Adjustments: When combined with moderate CYP3A4 inhibitors (diltiazem, verapamil, fluconazole): reduce colchicine dose by 50% or more. With strong CYP3A4 inhibitors: see interaction table.

Colchicine pricing is a controversial topic. In 2009, URL Pharma (now Takeda) received FDA approval for Colcrys after conducting required studies, which granted market exclusivity and caused prices to rise from pennies per pill to over $6 per pill ^[6].

Current pricing: - Brand-name Colcrys: $6-8 per 0.6 mg tablet ($180-240/month for prophylaxis) - Generic colchicine: $1-3 per tablet ($30-90/month) — available since 2015 - Mitigare (brand): Similar pricing to Colcrys

Cost-saving strategies: - Generic substitution: Multiple generic colchicine products are available and significantly cheaper than Colcrys - GoodRx coupons: Can reduce generic colchicine to $20-40 for a 30-day supply - Prescription discount programs: Some pharmacies offer colchicine on discount generic lists - Insurance coverage: Most insurers now cover generic colchicine at preferred tier - For acute flares: The low-dose regimen (1.8 mg total) uses only 3 tablets, keeping the per-flare cost manageable - Patient assistance: Takeda offers assistance programs for Colcrys for uninsured patients

Pregnancy (Category C): Colchicine crosses the placenta. Animal studies at high doses have shown teratogenic effects ^[1]. However, significant human experience in women with Familial Mediterranean Fever who have taken colchicine throughout pregnancy has been reassuring, with no clear increase in birth defects ^[7]. The current consensus is that colchicine should be continued during pregnancy in FMF patients because untreated FMF carries higher risks. For gout, colchicine should be avoided during pregnancy if possible.

Breastfeeding: Colchicine is excreted in breast milk. The infant dose is estimated at 10% of the weight-adjusted maternal dose. The AAP considers colchicine compatible with breastfeeding ^[8]. For FMF patients, continuation during breastfeeding is generally recommended.

Fertility: At therapeutic doses, colchicine may cause reversible oligospermia (reduced sperm count) in some men, though most studies in FMF patients have not shown clinically significant effects on fertility ^[1].

Generic colchicine 0.6 mg tablets have been available since 2015 and are manufactured by multiple companies, providing meaningful cost savings over brand-name products.

Colcrys (Takeda) was the first FDA-approved colchicine product in 2009, despite colchicine having been used for centuries as an unapproved drug. The approval process triggered a controversial price increase.

Mitigare (0.6 mg capsules) was approved in 2014 for gout flare prophylaxis only (not acute treatment). It is also available generically.

All generic colchicine products are FDA "AB" rated and therapeutically equivalent to their brand-name counterparts. The generic versions have substantially reduced the cost burden on patients.